Advertisement

Molecular and Cellular Biochemistry

, Volume 461, Issue 1–2, pp 37–46 | Cite as

Adiponectin receptor agonist AdipoRon induces apoptotic cell death and suppresses proliferation in human ovarian cancer cells

  • Amin A. RamzanEmail author
  • Benjamin G. Bitler
  • Douglas Hicks
  • Kelsey Barner
  • Lubna Qamar
  • Kian Behbakht
  • Theresa Powell
  • Thomas Jansson
  • Heidi Wilson
Article
  • 116 Downloads

Abstract

We tested the hypothesis that stimulation of adiponectin receptors with the synthetic agonist AdipoRon suppresses proliferation and induces apoptotic death in human high grade serous ovarian tumor cell lines and in ex vivo primary tumors, mediated by activation of 5′ AMP-activated protein kinase (AMPK) and inhibition of mechanistic target of rapamycin (mTOR). We determined the effect of AdipoRon on high grade serous ovarian tumor cells lines (OVCAR3, OVCAR4, A2780) and ex vivo primary tumor tissue. Western blotting analysis was performed to examine changes in activation of AMPK and mTOR signaling and flow cytometry was utilized to examine changes in cell cycle progression. Immunofluorescence of cleaved caspase-3 positive cells and flow cytometry of annexin V positive cells were used to determine changes in apoptotic response. The CyQUANT proliferation assay was used to assess cell proliferation. AdipoRon treatment increased AMPK phosphorylation (OVCAR3 P = 0.01; A2780 P = 0.02) but did not significantly alter mTOR activity. AdipoRon induced G1 cell cycle arrest in OVCAR3 (+ 12.1%, P = 0.03) and A2780 (+ 12.0%, P = 0.002) cells. OVCAR3 and OVCAR4 cells treated with AdipoRon underwent apoptosis based on cleaved caspase-3 and annexin V staining. AdipoRon treatment resulted in a dose dependent decrease in cell number versus vehicle treatment in OVCAR3 (−61.2%, P < 0.001), OVCAR4 (−79%, P < 0.001), and A2780 (−56.9%, P < 0.001). Ex vivo culture of primary tumors treated with AdipoRon resulted in an increase in apoptosis measured with cleaved caspase-3 immunohistochemistry. AdipoRon induces activation of AMPK and exhibits an anti-tumor effect in ovarian cancer cell lines and primary tumor via a mTOR-independent pathway.

Keywords

Ovarian cancer Adiponectin mTORC1 AMPK 

Notes

Acknowledgements

This research was supported in part by University of Colorado Department of Obstetrics and Gynecology Academic Enrichment Fund grant. The authors appreciate the contribution to this research made by E. Erin Smith, HTL(ASCP)CM QIHC, Allison Quador, HTL(ASCP)CM, and Jessica Arnold, HTL(ASCP)CM of the University of Colorado Denver Tissue Biobanking and Histology Shared Resource. This resource is supported in part by the Cancer Center Support Grant (P30CA046934). Flow cytometry was performed by the University of Colorado Cancer Center Flow Cytometry Shared Resource (supported by NCI Cancer Center Support Grant P30CA046934). We would also like to acknowledge that imaging was made possible by the University of Colorado Advanced Light Microscopy Core, supported in part by NIH/NCRR CCTSI grant UL1 RR025780. Contents are the authors’ sole responsibility.

Compliance with ethical standards

Conflict of interest

All authors declare that they have no conflicts of interest related to this work.

Supplementary material

11010_2019_3586_MOESM1_ESM.docx (66 kb)
Supplementary material 1 (DOCX 65 kb)

References

  1. 1.
    Siegel RL, Miller KD, Jemal A (2018) Cancer statistics, 2018. CA 68:7–30.  https://doi.org/10.3322/caac.21442 CrossRefPubMedGoogle Scholar
  2. 2.
    National Cancer Institute Cancer Stat Facts: ovarian cancerGoogle Scholar
  3. 3.
    Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Madry R, Christensen RD, Berek JS, Dorum A, Tinker AV, du Bois A, Gonzalez-Martin A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA, Investigators E-ON (2016) Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N Engl J Med 375:2154–2164.  https://doi.org/10.1056/NEJMoa1611310 CrossRefPubMedGoogle Scholar
  4. 4.
    Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83CrossRefGoogle Scholar
  5. 5.
    Combs TP, Marliss EB (2014) Adiponectin signaling in the liver. Rev Endocr Metab Disord 15:137–147.  https://doi.org/10.1007/s11154-013-9280-6 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Moon HS, Chamberland JP, Aronis K, Tseleni-Balafouta S, Mantzoros CS (2011) Direct role of adiponectin and adiponectin receptors in endometrial cancer: in vitro and ex vivo studies in humans. Mol Cancer Ther 10:2234–2243.  https://doi.org/10.1158/1535-7163.MCT-11-0545 CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Kim AY, Lee YS, Kim KH, Lee JH, Lee HK, Jang SH, Kim SE, Lee GY, Lee JW, Jung SA, Chung HY, Jeong S, Kim JB (2010) Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol 24:1441–1452.  https://doi.org/10.1210/me.2009-0498 CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Li G, Cong L, Gasser J, Zhao J, Chen K, Li F (2011) Mechanisms underlying the anti-proliferative actions of adiponectin in human breast cancer cells, MCF7-dependency on the cAMP/protein kinase-A pathway. Nutr Cancer 63:80–88.  https://doi.org/10.1080/01635581.2010.516472 CrossRefPubMedGoogle Scholar
  9. 9.
    Olsen CM, Green AC, Whiteman DC, Sadeghi S, Kolahdooz F, Webb PM (2007) Obesity and the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Eur J Cancer 43:690–709.  https://doi.org/10.1016/j.ejca.2006.11.010 CrossRefPubMedGoogle Scholar
  10. 10.
    Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ (2003) Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 348:1625–1638.  https://doi.org/10.1056/NEJMoa021423 CrossRefPubMedGoogle Scholar
  11. 11.
    Jin JH, Kim HJ, Kim CY, Kim YH, Ju W, Kim SC (2016) Association of plasma adiponectin and leptin levels with the development and progression of ovarian cancer. Obstet Gynecol Sci 59:279–285.  https://doi.org/10.5468/ogs.2016.59.4.279 CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Otokozawa S, Tanaka R, Akasaka H, Ito E, Asakura S, Ohnishi H, Saito S, Miura T, Saito T, Mori M (2015) Associations of serum isoflavone, adiponectin and insulin levels with risk for epithelial ovarian cancer: results of a case-control study. Asian Pac J Cancer Prev 16:4987–4991CrossRefGoogle Scholar
  13. 13.
    Okada-Iwabu M, Yamauchi T, Iwabu M, Honma T, Hamagami K, Matsuda K, Yamaguchi M, Tanabe H, Kimura-Someya T, Shirouzu M, Ogata H, Tokuyama K, Ueki K, Nagano T, Tanaka A, Yokoyama S, Kadowaki T (2013) A small-molecule AdipoR agonist for type 2 diabetes and short life in obesity. Nature 503:493–499.  https://doi.org/10.1038/nature12656 CrossRefPubMedGoogle Scholar
  14. 14.
    Li X, Yu Z, Fang L, Liu F, Jiang K (2017) Expression of adiponectin receptor-1 and prognosis of epithelial ovarian cancer patients. Med Sci Monit 23:1514–1521CrossRefGoogle Scholar
  15. 15.
    Tiwari A, Ocon-Grove OM, Hadley JA, Giles JR, Johnson PA, Ramachandran R (2015) Expression of adiponectin and its receptors is altered in epithelial ovarian tumors and ascites-derived ovarian cancer cell lines. Int J Gynecol Cancer 25:399–406.  https://doi.org/10.1097/igc.0000000000000369 CrossRefPubMedGoogle Scholar
  16. 16.
    Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, Jordan VC, Bradford AP (2012) DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol 127:241–248.  https://doi.org/10.1016/j.ygyno.2012.06.017 CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Krishan A (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66:188–193CrossRefGoogle Scholar
  18. 18.
    McCarty KS Jr, Szabo E, Flowers JL, Cox EB, Leight GS, Miller L, Konrath J, Soper JT, Budwit DA, Creasman WT et al (1986) Use of a monoclonal anti-estrogen receptor antibody in the immunohistochemical evaluation of human tumors. Cancer Res 46:4244s–4248sPubMedGoogle Scholar
  19. 19.
    Li W, Saud SM, Young MR, Chen G, Hua B (2015) Targeting AMPK for cancer prevention and treatment. Oncotarget 6:7365–7378.  https://doi.org/10.18632/oncotarget.3629 CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Kwon HK, Bae GU, Yoon JW, Kim YK, Lee HY, Lee HW, Han JW (2002) Constitutive activation of p70S6 k in cancer cells. Arch Pharm Res 25:685–690CrossRefGoogle Scholar
  21. 21.
    Hoffmann M, Gogola J, Ptak A (2018) Adiponectin reverses the proliferative effects of estradiol and IGF-1 in human epithelial ovarian cancer cells by downregulating the expression of their receptors. Horm Cancer 9:166–174.  https://doi.org/10.1007/s12672-018-0331-z CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    National Cancer Institute The Cancer Genome AtlasGoogle Scholar
  23. 23.
    Domcke S, Sinha R, Levine DA, Sander C, Schultz N (2013) Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4:2126.  https://doi.org/10.1038/ncomms3126 CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Yung MM, Ngan HY, Chan DW (2016) Targeting AMPK signaling in combating ovarian cancers: opportunities and challenges. Acta Biochim Biophys Sin 48:301–317.  https://doi.org/10.1093/abbs/gmv128 CrossRefPubMedGoogle Scholar
  25. 25.
    Taliaferro-Smith L, Nagalingam A, Zhong D, Zhou W, Saxena NK, Sharma D (2009) LKB1 is required for adiponectin-mediated modulation of AMPK-S6 K axis and inhibition of migration and invasion of breast cancer cells. Oncogene 28:2621–2633.  https://doi.org/10.1038/onc.2009.129 CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Cheaib B, Auguste A, Leary A (2015) The PI3 K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer 34:4–16.  https://doi.org/10.5732/cjc.014.10289 CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Xu J, Ji J, Yan XH (2012) Cross-talk between AMPK and mTOR in regulating energy balance. Crit Rev Food Sci Nutr 52:373–381.  https://doi.org/10.1080/10408398.2010.500245 CrossRefPubMedGoogle Scholar
  28. 28.
    Liu Y, Shi L, Liu Y, Li P, Jiang G, Gao X, Zhang Y, Jiang C, Zhu W, Han H, Ju F (2018) Activation of PPARgamma mediates icaritin-induced cell cycle arrest and apoptosis in glioblastoma multiforme. Biomed Pharmacother 100:358–366.  https://doi.org/10.1016/j.biopha.2018.02.006 CrossRefPubMedGoogle Scholar
  29. 29.
    Zhuang Y, Miskimins WK (2008) Cell cycle arrest in metformin treated breast cancer cells involves activation of AMPK, downregulation of cyclin D1, and requires p27Kip1 or p21Cip1. J Mol Signal 3:18.  https://doi.org/10.1186/1750-2187-3-18 CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Yamauchi T, Kamon J, Minokoshi Y, Ito Y, Waki H, Uchida S, Yamashita S, Noda M, Kita S, Ueki K, Eto K, Akanuma Y, Froguel P, Foufelle F, Ferre P, Carling D, Kimura S, Nagai R, Kahn BB, Kadowaki T (2002) Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288–1295.  https://doi.org/10.1038/nm788 CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Wu Y, Song P, Zhang W, Liu J, Dai X, Liu Z, Lu Q, Ouyang C, Xie Z, Zhao Z, Zhuo X, Viollet B, Foretz M, Wu J, Yuan Z, Zou MH (2015) Activation of AMPKalpha2 in adipocytes is essential for nicotine-induced insulin resistance in vivo. Nat Med 21:373–382.  https://doi.org/10.1038/nm.3826 CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Awazawa M, Ueki K, Inabe K, Yamauchi T, Kubota N, Kaneko K, Kobayashi M, Iwane A, Sasako T, Okazaki Y, Ohsugi M, Takamoto I, Yamashita S, Asahara H, Akira S, Kasuga M, Kadowaki T (2011) Adiponectin enhances insulin sensitivity by increasing hepatic IRS-2 expression via a macrophage-derived IL-6-dependent pathway. Cell Metab 13:401–412.  https://doi.org/10.1016/j.cmet.2011.02.010 CrossRefPubMedGoogle Scholar
  33. 33.
    Habeeb BS, Kitayama J, Nagawa H (2011) Adiponectin supports cell survival in glucose deprivation through enhancement of autophagic response in colorectal cancer cells. Cancer Sci 102:999–1006.  https://doi.org/10.1111/j.1349-7006.2011.01902.x CrossRefPubMedGoogle Scholar
  34. 34.
    Liu J, Lam JB, Chow KH, Xu A, Lam KS, Moon RT, Wang Y (2008) Adiponectin stimulates Wnt inhibitory factor-1 expression through epigenetic regulations involving the transcription factor specificity protein 1. Carcinogenesis 29:2195–2202.  https://doi.org/10.1093/carcin/bgn194 CrossRefPubMedGoogle Scholar
  35. 35.
    Wang Y, Lam JB, Lam KS, Liu J, Lam MC, Hoo RL, Wu D, Cooper GJ, Xu A (2006) Adiponectin modulates the glycogen synthase kinase-3beta/beta-catenin signaling pathway and attenuates mammary tumorigenesis of MDA-MB-231 cells in nude mice. Cancer Res 66:11462–11470.  https://doi.org/10.1158/0008-5472.Can-06-1969 CrossRefPubMedGoogle Scholar
  36. 36.
    Motoshima H, Wu X, Sinha MK, Hardy VE, Rosato EL, Barbot DJ, Rosato FE, Goldstein BJ (2002) Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone. J Clin Endocrinol Metab 87:5662–5667.  https://doi.org/10.1210/jc.2002-020635 CrossRefPubMedGoogle Scholar
  37. 37.
    Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, Romero IL, Carey MS, Mills GB, Hotamisligil GS, Yamada SD, Peter ME, Gwin K, Lengyel E (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17:1498–1503.  https://doi.org/10.1038/nm.2492 CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Messaggio F, Mendonsa AM, Castellanos J, Nagathihalli NS, Gorden L, Merchant NB, VanSaun MN (2017) Adiponectin receptor agonists inhibit leptin induced pSTAT3 and in vivo pancreatic tumor growth. Oncotarget 8:85378–85391.  https://doi.org/10.18632/oncotarget.19905 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Division of Gynecologic Oncology, Department of Obstetrics and GynecologyUniversity of Colorado School of MedicineAuroraUSA
  2. 2.Division of Reproductive Sciences, Department of Obstetrics and GynecologyUniversity of Colorado School of MedicineAuroraUSA

Personalised recommendations